OAS2 Gene Expression Testing for Respiratory Virus Mortality Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the mortality risk of patients infected with respiratory viruses like SARS-COV-2 are limited by implementation time, lack of standardization, and high costs, making it difficult to use in routine clinical settings for timely patient assessment.
Innovation Solution
An in vitro method involving the measurement of OAS2 gene expression levels in a biological sample, optionally combined with additional genes, and comparison to predetermined reference values to determine the risk of death, using RT-PCR for quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mixed flow cytometry approaches and multiplex analysis are used to characterize immune profile, then comprehensive immune characterization is achieved, but implementation time increases and reproducibility decreases
Solution Approach 1:
The patent extracts the essential predictive information from complex immune profiles by identifying a single key biomarker (OAS2 gene expression) that captures the most critical prognostic signal. This extraction approach maintains measurement precision for mortality risk assessment while eliminating the time-consuming nature of comprehensive multi-parameter immune profiling.
Solution Approach 2:
The patent segments the complex immune response into distinct functional categories (type I interferon signaling, inflammatory response, adaptive immunity) and identifies that OAS2 expression alone can effectively represent the critical type I interferon pathway status for mortality prediction, thereby simplifying the overall assessment without losing essential diagnostic information.
2Measurement precision
If mixed flow cytometry approaches and multiplex analysis are used to characterize immune profile, then comprehensive immune characterization is achieved, but reproducibility across cohorts decreases
Solution Approach 1:
By extracting the single most prognostically relevant signal (OAS2 gene expression) from the complex immune profile, the patent achieves high reproducibility across different cohorts and laboratories. This single-marker approach eliminates the variability inherent in multi-parameter flow cytometry and multiplex analyses, providing consistent results regardless of the specific cohort or laboratory performing the assessment.
3Measurement precision
If mixed flow cytometry approaches and multiplex analysis are used to characterize immune profile, then comprehensive immune characterization is achieved, but cost increases
Solution Approach 1:
The patent extracts only the essential prognostic information needed for mortality risk assessment by measuring a single biomarker (OAS2 gene expression) rather than comprehensive immune profiles. This dramatically reduces the cost of testing while maintaining the ability to accurately predict mortality risk, making the assay accessible for routine clinical use.
Solution Approach 2:
The patent segments the expensive multi-parameter immune profiling into a focused assessment of type I interferon signaling status through OAS2 expression alone. This segmentation approach maintains the critical diagnostic information needed for prognosis while eliminating the substantial costs associated with comprehensive flow cytometry and multiplex analysis.
4Measurement precision
If comprehensive immune profile analysis is used, then detailed immune characterization is achieved, but ease of operation decreases
Solution Approach 1:
The patent extracts the essential prognostic signal from complex immune profiles, reducing the operational complexity to a single gene expression measurement. This makes the test easy to perform in routine clinical settings without requiring specialized flow cytometry expertise or complex data analysis pipelines, while still providing accurate mortality risk prediction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and cost-effective assessment of mortality risk at the patient's bedside or in a central laboratory, providing personalized treatment options for patients with respiratory viruses.
Implementation Method 1
The expression level of the OAS2 gene is measured in a biological sample from the subject using RT-PCR
Data Source
AI summary
The invention relates to an in vitro or ex vivo method for determining the risk of death for a subject infected with a respiratory virus, said method comprising the steps of measuring, in a biological sample from said subject, the expression level of the OAS2 gene, and comparing the expression level thus measured or a value derived from this amount to a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death for the subject when a sub-expression of the OAS2 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of OAS2 can be supplemented by a measurement of one or more additional genes such as C3ARI, CD177, ADGRE3, CIITA, IL-10, ILIR2, CD74, TDRD9 and combinations thereof. Kits for measuring the expression of OAS2 and optionally one or more additional genes are also disclosed.